RT Journal Article SR Electronic T1 Quality of life after transcatheter or surgical aortic valve replacement using the Toronto Aortic Stenosis Quality of Life Questionnaire JF Open Heart JO Open Heart FD British Cardiovascular Society SP e001821 DO 10.1136/openhrt-2021-001821 VO 8 IS 2 A1 Simon Kennon A1 Rima Styra A1 Nikolaos Bonaros A1 Lukas Stastny A1 Mauro Romano A1 Thierry Lefèvre A1 Carlo Di Mario A1 Pierluigi Stefàno A1 Flavio Luciano Ribichini A1 Dominique Himbert A1 Marina Urena-Alcazar A1 Jorge Salgado-Fernandez A1 Jose Joaquin Cuenca Castillo A1 Bruno Garcia A1 Cornelia Deutsch A1 Lenka Sykorova A1 Jana Kurucova A1 Martin Thoenes A1 Claudia Lüske A1 Peter Bramlage A1 Derk Frank YR 2021 UL http://openheart.bmj.com/content/8/2/e001821.abstract AB Background The Toronto Aortic Stenosis Quality of Life Questionnaire (TASQ) is a validated instrument for assessing quality of life (QoL) in patients with severe aortic stenosis (AS). In this study, we evaluated health status outcomes, based on the TASQ, in patients with severe AS undergoing transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR).Methods The TASQ registry was a prospective observational registry. Patients with severe AS from nine centres in Europe and one in Canada underwent either SAVR or transfemoral TAVR. Patients completed the TASQ, Kansas City Cardiomyopathy Questionnaire and Short Form-12 V.2 prior to the intervention, predischarge, and at 30-day and 3-month follow-ups. Primary end point was the TASQ score.Results In both the TAVR (n=137) and SAVR (n=137) cohorts, significant increases were observed in all three scores. The overall TASQ score improved as did all but one of the individual domains at 3 months after the intervention (p<0.001). TASQ health expectations were the only domain which worsened (p<0.001). Across TASQ subscores, significant changes were evident from the time of discharge in the TAVR and 30-day follow-up in the SAVR cohort. In a categorical analysis of the TASQ, 39.7% of the TAVR group and 35.0% of the SAVR group had a substantially improved health status at 3 months compared with baseline.Conclusions The TASQ captured changes in QoL among patients with severe AS who were treated with TAVR or SAVR. QoL improved substantially after either intervention, as indicated by changes in the TASQ overall score at 3 months.Trial registration number NCT03186339.Data are available upon reasonable request.